Immunogenicity of Human Papillomavirus Virus Vaccine in a High-risk and Understudied Group: Female Sex Workers Authors: Nguyen Van Trang, Le Anh Tuan, Chu Thi Ngoc Mai, Le Thi Khanh Ly, Tran Hoang My Lien, Nguyen Thanh Chung, Dao Thi Thanh Huyen, Nguyen Thi To Uyen, Nham Thi Tuyen Thanh, Tran Thi Hong Nhung, Chau Quang, Claire Von Mollendorf, Gerald Murray, Suzanne M Garland, Kathryn Bright, Paul V Licciardi, Kim Mulholland, Zheng Quan Toh Published: 2026 ABSTRACT AbstractBackgroundFemale sex workers (FSW) have multiple sexual partners and are at higher risk of human papillomavirus virus (HPV) infection. They could be a target group for HPV vaccination, but their expected immune response to the HPV vaccine is unclear due to potential exposure to the virus.MethodsWe conducted a pilot study (NCT04590521) in Hai Phong, Vietnam to evaluate HPV vaccine immunogenicity among FSW aged 18–26 years. All participants received the standard 3-dose schedule (0, 2, and 6 months) of the quadrivalent Gardasil vaccine (4vHPV). Cervical swabs were collected at time of vaccination to detect high-risk HPV DNA and cervical abnormalities. Blood samples were collected at baseline and at 2, 3, 6, and 7 months after the first dose to determine neutralizing antibody (nAb) responses to HPV16 and HPV18, as well as related HPV52 and HPV58.ResultsA total of 63 FSW with a median age of 23.4 years (IQR, 21.6–25.4 years) were recruited. Prevalence of any high-risk HPV type and HPV16/18 infection at baseline was 28.6% (18/63) and 9.5% (6/63), respectively. Following the first dose, 90% and 55% of individuals were seropositive for HPV16 and HPV18, respectively. By month 7, all participants were seropositive to both HPV16 and HPV18. Higher nAb responses were observed among HPV-DNA–negative participants at baseline compared with HPV-DNA–positive participants after 2 and 3 doses (HPV16, geometric mean ratio [GMR] 2.97 and 1.63, P < .05; HPV18, GMR 2.83 and 1.49, P = .06).ConclusionsThree doses of 4vHPV elicited robust nAb to HPV16 and HPV18 among FSW. Further studies are needed to evaluate the effectiveness of HPV vaccination in FSW. Clinical Trials Registration.NCT04590521.Keywords: HPV vaccine, female sex workers, immunogenicity, Vietnam, HPV infection Multiple sexual partners (defined as more than 5) over a women's lifetime is a risk factor for human papillomavirus virus (HPV) infection and cervical cancer [1, 2]. Female sex workers (FSWs) are at a significantly higher risk of HPV infection (4–10 times) and cervical precancers (2–5 times) than the general population [3–9]. This elevated risk is driven by several risk factors, including a higher number of sexual partners, reduced access to health care services, as well as limited knowledge of HPV, HPV vaccines, and cervical cancer [10]. In particular, the disparities in access to health care services such as HPV vaccination, cervical cancer screening, and treatment are more pronounced in low- and middle-income countries (LMICs) than in high-income settings [11, 12]. The pooled estimate of HPV prevalence among FSWs globally is around 40%, with higher rates among Western Pacific and African Regions [6]. FSW are also known to be commonly infected with multiple HPV types [4, 13], and are likely to play a major role in HPV transmission within the community [6]. In settings lacking widespread/national vaccination programs, targeted vaccination of high-risk groups may reduce the burden of HPV infection and cervical cancer until access to HPV vaccines through national immunization programs is feasible. Current HPV vaccines are prophylactic and not therapeutic so do not clear existing HPV infections or lesions [14]. However, HPV vaccination can generate immunity to HPV types not yet encountered and may also protect against reinfection with the same type, thereby reducing the overall risk of HPV-associated diseases, including cervical cancer in women [15]. In addition, high vaccine efficacy against cervical dysplasia and significant boosting of antibody responses have been reported among seropositive, HPV-DNA–negative women at the time of vaccination [16, 17]. Current HPV vaccine dosing recommendations are based on age and immunocompetence, and do not consider specific high-risk populations such as FSWs. There is limited understanding of the potential differences in immunogenicity of the HPV vaccine in high-risk groups due to their past/current HPV exposure. In Vietnam, although the HPV vaccine has been licensed since 2009, it has only been available through the private market. As a result, access remained out of reach for many, with less than 27% of females in the target age group vaccinated, and access varies considerably between regions [18, 19]. The majority of Vietnamese women reported that their first sexual intercourse was between 20 and 24 years old [20]. We previously conducted an epidemiological survey of HPV infection and sexual risk behaviors among FSWs in Vietnam [4]. We found that Vietnamese FSWs (18–45 years of age) are 6 times more likely to be infected with any HPV than university students (18–26 years of age) [4]. Approximately 20% of FSW were infected with 1 or more high-risk HPV types, with HPV52 and HPV58 among the most detected [4]. Both HPV52 and 58 belong to the alpha-9 clade of high-risk HPV, along with HPV16 [21], and have the potential for cross-reactive immunity following HPV vaccination [22]. In this study, we evaluated the immunogenicity of Gardasil HPV vaccine (4vHPV) in FSWs aged 18–26 years in a pilot study based in Hai Phong, Vietnam. Here we describe the HPV infection rates and neutralizing antibody responses to HPV16, HPV18, HPV52, and HPV58. METHODS Study Design and Participants We conducted a single-arm, pilot study to determine HPV vaccine immunogenicity in Hai Phong, Vietnam. Women with a reported age of 18–26 years, based in Hai Phong, Vietnam and who had engaged in commercial sex in the last month were recruited. All participants received 3 doses of 4vHPV according to the licensed schedule (0, 2, 6 months) (Figure 1). This study was approved by the Royal Children's Hospital Human Research Ethics Committee, Australia (HREC 2019.225) and by the Ethics Committee of the National Institute of Hygiene and Epidemiology (NIHE), Vietnam (IRB number, NIHE IRB-05/2022). The study was registered on Clinicaltrials.gov (NCT04590521). Study overview including timing of vaccination and sample collection. Abbreviations: 4vHPV, quadrivalent human papillomavirus virus Gardasil vaccine; FSW, female sex worker. Created in https://BioRender.com Study Procedures Participants were recruited at Hai Son Commune Health Station, Do Son district, Hai Phong city, Vietnam. Participants were recruited by the team from the Center for Supporting Community Development Initiatives, a non-governmental organization implementing community-based programs for high-risk populations in Hai Phong, Vietnam since 2016. Written informed consent was obtained from all participants prior to enrolment in the study. Participants were excluded if they were pregnant, living with human immunodeficiency virus (HIV), had received any HPV vaccine previously, had an axillary temperature greater than 38°C, had known allergies to any vaccine component, or were unable to provide informed consent. At recruitment, a questionnaire administered by the study staff was completed, which included participant demographics and knowledge about HPV and cervical cancer. Participants were observed for any adverse events (ie, faintness, anaphylaxis or allergies, wheezing/rash) for 30 minutes following vaccination. At subsequent visits, a questionnaire was completed to record the participant's wellbeing and any adverse events, including whether the participant experienced any of the following symptoms based on recollection: headache, faintness, fever, fatigue, nausea, vomiting, diarrhea, loss of appetite, muscle or joint pain, redness, swelling or pain at injection site, convulsion, rash, or hospitalization, or required any sort of medical attention since the last visit. Any serious adverse events (defined as any adverse event that met 1 of the following: death, life-threatening complication, hospitalization, or persistent/significant disability) were also documented. All samples were collected by study staff based at the Hai Son Commune Health Station, Hai Phong. Cervical swab samples were taken by gynecologists at baseline, and prior to vaccine doses given at subsequent visits at 2 and 6 months. Cervical swab samples were separated into 2 aliquots. One aliquot was used for HPV-DNA detection, and the other was used for a Papanicolaou test using PathTezt EasyVial (EV- cytopathologists, and any discrepancies were resolved by joint review to ensure quality control. Blood samples were collected by health nurses at baseline, and at 2, 3, 6, and 7 months (ie, 1 month after the third dose) after the first vaccine dose to assess neutralizing antibody responses. Laboratory Methods HPV-DNA testing was performed using the HPV Genotypes 14 Real-TM Quant kit (Sacace) that detects 14 oncogenic HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) according to the manufacturer's protocol. Using the calibration standards and calculation formula provided by the HPV testing kit, cycle threshold values were converted into HPV-DNA concentration. The β-globulin gene was used as an internal control. Samples negative for β-globulin were considered invalid and were not included in the analysis. Blood samples were separated into serum by centrifugation, and serum was frozen at −80°C at NIHE, Vietnam until use. The neutralizing antibodies against HPV types 16, 18, 52, and 58 were measured using the HPV pseudovirion-based neutralization assay as previously described [18]. The neutralizing titer (ED50) is defined as the highest serum dilution that reduces the secreted alkaline phosphatase activity by at least 50% in comparison to a control (pseudovirions without serum). For anti-HPV16 and anti-HPV18, a sample with an ED50 value of ≥ 100 was considered HPV seropositive; seronegative samples were given a value of 50. For anti-HPV52 and anti-HPV58, a sample with an ED50 value of ≥ 50 was considered HPV seropositive. As cross-reactive antibodies are typically present at lower levels than vaccine-type antibodies, a lower seropositivity cut off was used to avoid missing potential seroconversion events [23]. Seronegative samples were given a value of 25. Statistical Analysis Participant data were double entered into a database using EpiData software. Participant baseline characteristics were summarized; continuous variables were reported as medians and interquartile ranges (IQR). Persistent HPV infection was defined as the same HPV type detected at baseline and at 6 months postvaccination. The exact binomial Clopper-Pearson method was used to estimate 95% confidence intervals (CI) of HPV infection. Seropositivity to HPV16, HPV18, HPV52, and HPV58 is summarized in percentage and 95% CI. Neutralizing antibody titers against HPV16, HPV18, HPV52, and HPV58 were reported in geometric mean titers (GMTs) and 95% CI. In addition, the HPV neutralizing antibody titers against HPV16 and HPV18 were analyzed by participant baseline HPV-DNA status for the respective types, for any high-risk HPV-DNA status at baseline, as well as baseline HPV serostatus. For these analyses, the neutralizing antibody titers were compared using the Mann-Whitney U test. The geometric mean ratio (GMR) by HPV-DNA status at baseline was calculated by dividing the GMT of HPV-DNA–negative by that of HPV-DNA–positive. Based on a previous study on young women aged 15–25 years who received a 3-dose regimen [24], where 90% achieved neutralizing antibody levels greater than 180-fold from baseline, a sample size of n = 60 provided 82% power to detect a 14% reduction in neutralizing antibody levels between the FSW group compared to young women (non-FSW) using a 1-sided confidence level of 95%. All statistical analyses were performed using GraphPad Prism software, version 5.0. A P value < .05 was considered statistically significant for all analyses. RESULTS A total of 63 participants were recruited from September 2022 to April 2023. Twelve participants were lost to follow-up by the final study visit, with 51 participants providing a blood sample at 7 months postvaccination. Baseline characteristics of participants are presented in Table 1. The median age was 23.4 years (IQR, 21.6–25.4 years). Nearly three-quarters of participants (46/63, 73.0%) had attained at least a high school education. The median number of customers per day was 10, and 68.3% (43/63) of participants reported always using condoms. Table 1.Participants’ Baseline CharacteristicsVariableValueAge, y, median (IQR)23.4 (21.6–25.4)Marital status Single33 (52.4) Married20 (31.7) Separated/divorced/widowed10 (15.9)Highest education attained Elementary/middle school17 (27.0) High school or higher46 (73.0)Smoking status2 (3.2)Any alcohol use in the last wk25 (39.7)Age at initiation of sex work, y, median (IQR)18.0 (18.0–19.0)Average No. of customers/day, median (IQR)10.0 (7.0–15.0)Time since last sexual intercourse, h, median (IQR)10.0 (9.0–17.0)No. of sexual intercourse in the last 24 h, median (IQR)6.0 (5.0–8.0)Proportion of sexual intercourse with clients using condom Sometimes5 (7.9) Often15 (23.8) Always43 (68.3)Data are No. (%) except where indicated. Participants’ Baseline Characteristics Data are No. (%) except where indicated. At baseline, 28.6% (18/63) of participants were infected with at least 1 high-risk HPV type (Supplementary Figure 1A). No cervical abnormalities were found at either baseline or 6 months after dose 1. The most prevalent high-risk HPV type was HPV51 (9.5%, 9/63), followed by HPV68 (6.3%, 4/63), HPV16, and HPV18 (both 4.8%, 3/63) (Figure 2). Four participants had infection with 2 or more HPV types (Supplementary Figure 1A). At month 6, 7 individuals out of 51 had persistent genotype-specific HPV infection; 3 had HPV51, 2 had HPV18, 1 HPV16, and 1 HPV45 (Figure 2 and Supplementary Figure 1A). Among those with HPV infection, no consistent pattern of viral load change following vaccination was observed over the 6-month period (Supplementary Figure 1B). Prevalence of high-risk HPV genotypes at baseline (light purple) and at month 6 (dark purple) among study participants. Error bars represent 95% CI. Abbreviations: HPV, human papillomavirus virus; n, number of participants. Prior to HPV vaccination, 3 and 4 participants were seropositive for HPV16 (4.8%) and HPV18 (6.3%), respectively, of which 1 was seropositive for both HPV types (Figure 3). Among those seropositive for HPV16 and HPV18, 1 participant had HPV16 DNA detected and 1 had HPV18 DNA detected, respectively (Supplementary Figure 1A). Two months following the first HPV vaccine dose, 90% (54/60) and 55% (33/60) were seropositive for HPV16 and HPV18, respectively. Approximately 90% of participants were seropositive for both HPV16 and HPV18 following the second vaccine dose, and 100% were seropositive for both HPV types after the third dose (Figure 3). Seropositivity to HPV52 and HPV58 were similar over the 6-month period, ranged from 8.3% to 15.7% and 5.2% to 9.8%, respectively (Figure 3). Seropositivity rates to HPV16, 18, 52, and 58 at each study visits. Blue bars, HPV16; green bars, HPV18; dark grey bars, HPV52; light grey bars, HPV58. Number of participants at each study visit were day 0, n = 63; 2 months, n = 60; 3 months, n = 58; 6 months, n = 55; 7 months, n = 51. Seropositivity is defined as ED50 ≥ 100 for HPV16/18 and ED50 ≥ 50 for HPV52/58. Error bars represent 95% CI. Abbreviations: ED50, 50% effective dose; HPV, human papillomavirus virus. Overall, HPV16 and HPV18 neutralizing antibody GMTs increased following each vaccine dose, peaking at 1 month after the third dose (ED50 HPV16, 5220 [95% CI, 4182–6514]; ED50 HPV18, 2043 [95% CI, 1613–2589]; Figure 4A). However, 5 individuals (3 were positive for high-risk HPV DNA at baseline) were seronegative for both HPV16 and HPV18 after 2 doses. Antibody GMTs for both HPV16 and HPV18 declined by approximately 2-fold between month 3 (1 month after the second dose) and month 6 (before the third dose) (Figure 4A). Some participants had increased HPV52 and HPV58 neutralizing antibodies following 4vHPV vaccination (Supplementary Figure 2). Anti-HPV16 and anti-HPV18 neutralizing antibody titers at each study visit. A, Neutralizing antibody responses of total cohort. Red arrows represent time of vaccination. Green line and green shaded area represent GMT and 95% CI. B, Neutralizing antibody responses by high-risk HPV infection status at baseline. Black dotted line indicates seropositivity titer. Solid black lines represent participants positive at baseline for HPV16 DNA or HPV18 DNA. Blue line and shaded area represent GMT and 95% CI of high-risk HPV-DNA–negative participants at baseline, while red line and shaded area represent GMT and 95% CI of high-risk HPV-DNA–positive participants at baseline. Abbreviations: GMT, geometric mean titer; HPV, human papillomavirus virus. Among participants with either HPV16 DNA or HPV18 DNA detected at baseline, there was no clear evidence of enhanced or diminished HPV16-specific or HPV18-specific antibody responses compared to those uninfected with HPV16/18, likely due to the small number of HPV16/18-DNA–positive individuals (Figure 4B). However, FSWs who were HPV-DNA positive for any high-risk HPV types at the time of vaccination had overall lower antibody GMTs to HPV16 and HPV18 compared with those who were HPV-DNA negative (Figure 4B and Supplementary Table 1). These differences were statistically significant 1 month after 2 doses (month 3) for both HPV16 and HPV18 (GMR HPV-DNA negative/positive HPV16, 2.97 [95% CI, 1.98–4.45] and HPV18, 2.83 [95% CI, 2.30–3.49]), as well as 1 month after 1 dose for HPV18 (GMR, 1.89 [95% CI, 1.79–2.03]), and 1 month after 3 doses for HPV16 (GMR, 1.63 [95% CI, 1.47–1.81]) (Supplementary Table 1). Among participants who were seropositive for HPV16 or 18 at the time of vaccination, we observed higher HPV16/18 neutralizing antibody GMTs following vaccination compared to those who were seronegative, although this was only statistically significant for HPV18 (Supplementary Figure 3). Among the participants, 17 (28.3%), 22 (37.9%), and 4 (7.9%) women reported experiencing at least 1 adverse event after the first, second, and third doses, respectively; all were mild in nature and self-limiting. The most commonly reported events included pain and redness at the injection site, headache, and delayed menstruation (Supplementary Table 2). DISCUSSION This study found that 3 doses of the 4vHPV vaccine elicited strong HPV16 and HPV18 neutralizing antibody responses among FSWs, with 100% seropositivity achieved after the third dose. Although FSWs who were HPV-DNA positive at the time of the first vaccination generated overall lower neutralizing antibody responses after each vaccine dose compared to those who were HPV-DNA negative, they still mounted robust immune responses following the third dose. The clinical implication of this lower antibody response is unclear, because there is no identified antibody level for protection [14]. Vaccine effectiveness and transmission studies will help determine the broader public health benefits of vaccinating this high-risk group. While there are multiple studies documenting high HPV prevalence (up to 85%) among FSWs [4, 6, 13, 25–27], HPV vaccine immunogenicity studies are limited in this population. This is because they are hard to reach, and HPV vaccination is prophylactic and most effective prior to sexual debut. To our knowledge, there is only 1 published study examining HPV vaccine immunogenicity in FSW [28]. The study, conducted in Peru, found 3 doses of 4vHPV was immunogenic in FSWs aged 18–26 years, and those who were seropositive or HPV-DNA negative prior to receiving the vaccine had a higher antibody level than those who were seronegative or HPV-DNA positive [28]. These findings are consistent with our observations, although our sample size among vaccine-type–seropositive individuals was small, which may have limited our ability to detect any significant differences, especially against HPV16. Notably, the study population in Peru had a higher baseline HPV16/18 exposure (54.2% HPV-DNA positivity or seropositivity) [24], compared with our Vietnam cohort (11.1%). Our study is the first to document neutralizing antibody data following each vaccine dose, whereas the Peru study only reported data at baseline and 1 month after the third dose. Earlier clinical trial studies have also found significant boosting of antibody responses among seropositive, HPV-DNA–negative women at the time of vaccination [16, 17]. Additionally, the HPV vaccine was still highly immunogenic among FSWs who were HPV-DNA positive at the time of the first vaccination. Taken together, while HPV vaccination does not clear existing infections or accelerate their clearance [14], it can still offer protection to FSW against vaccine-type HPV (higher oncogenic potential) with which they are not currently infected. This applies not only to FSW but also to individuals who are currently infected with HPV or have had prior HPV infections. Furthermore, vaccination of FSW may also limit transmission of the HPV types they are most likely to acquire from their clients [29]. The World Health Organization recommends 2 or 3 HPV vaccine doses for individuals aged > 20 years, while those aged ≤ 20 years are recommended to receive 1 or 2 doses, except for specific groups such as those who are immunocompromised [30]. As older adults generate lower immune responses compared to adolescents following HPV vaccination [31, 32], these recommendations are based on age rather than individual risk of HPV infection or cervical cancer. FSWs may generate lower antibody responses due to reduced immune competence with older age [33–35] or coinfections, including other sexually transmitted infections [36], which may interfere with vaccine responses. Indeed, direct comparison with a previous study of women 18–26 years of age (non-FSW) who received 3 doses of 4vHPV [24], and employing a similar assay to measure neutralizing antibodies, showed that FSWs in our study, regardless of current or prior HPV infection, elicited approximately half the GMT for HPV16 (GMR, 0.50; 95% CI, 0.48–0.52), while HPV18 GMTs were comparable between the 2 groups (GMR, 1.10; 95% CI, 1.07–1.13) (Supplementary Figure 4). This difference may, however, reflect variation in study populations (Canada vs Vietnam). A single HPV vaccine dose schedule for individuals > 20 years of age is not currently recommended but is of growing scientific interest. Our data suggest that protection conferred by a single dose may be genotype dependent; around 90% seroconverted for HPV16 but only about half seroconverted for HPV18, consistent with the lower HPV18 immunogenicity observed in other studies [37, 38]. While HPV neutralizing antibodies are thought to be the mechanism of protection against HPV infection, the level required for protection has not been identified. It is possible that current assays may not be sufficiently sensitive to detect low-level HPV antibody responses [39]. Additionally, other immune mechanisms such as antibody-effector functions, mucosal responses, and/or cellular immunity may also contribute to protection [35, 40, 41]. Whether a single dose is sufficient for protection in FSWs needs further evidence from effectiveness studies. FSW have multiple sexual partners, placing them at an increased risk of HPV infection and cervical cancer. They are also more likely to harbor multiple HPV infections [4, 6, 13, 25–27], contributing to HPV transmission. Vaccination may reduce HPV transmission, although current evidence is inconsistent [42, 43]. Not all women develop immunity following natural HPV infection; hence, the combination of HPV vaccination and cervical screening is the best strategy to prevent cervical cancer. However, in many LMICs, implementation of either strategy can be challenging due to the high vaccine costs and logistical difficulties [44]. HPV vaccine has not yet been introduced into the national immunization program in Vietnam, and vaccine coverage remains low (< 27%) and varies considerably between regions and populations [18–20]. There is a significant population of FSW in Vietnam (> 300 000) and also other LMICs in Asia [45]. Therefore, targeted HPV vaccination of FSW may be one option to greatly reduce the risk and treatment of cervical cancer until the establishment of national HPV vaccination programs. A key strength of our study is the successful engagement and longitudinal follow-up of a vulnerable and highly mobile population—a group that is often underrepresented in HPV vaccine research. To our knowledge, this is only the second study to evaluate HPV vaccine immunogenicity among FSWs, providing valuable insights into a population at high risk of persistent HPV infection and cervical cancer. Several limitations should be considered. First, our findings may not be generalizable to FSW populations in other countries due to potential differences in epidemiology, HPV genotype distribution, and baseline immunity. Second, the immunogenicity data may not be directly extrapolated to other licensed HPV vaccines with different antigen compositions or adjuvant systems. Third, while the single-arm design precludes direct, concurrent comparisons with other populations, the intent of this pilot study was to establish vaccine immunogenicity and assess the feasibility of vaccine research in FSWs in Vietnam. Fourth, the small sample size in our study may have underestimated the true prevalence of HPV16/18 (both by HPV DNA and seroprevalence) in the population and should be interpreted with caution. Lastly, due to funding and logistical constraints, HPV-DNA and neutralizing antibodies to HPV6 and HPV11 were not measured, as analyses were focused on the oncogenic HPV types, including HPV52 and HPV58, which are most commonly detected in this population [4]. In conclusion, 3 doses of 4vHPV generate robust neutralizing antibody responses to HPV16 and 18 among FSW, with all participants seroconverting. A single dose of 4vHPV was also immunogenic for HPV16 but lower for HPV18. Future studies focused on optimizing HPV vaccination strategies among vulnerable populations will be critical to maximizing the public health impact of HPV and cervical cancer prevention programs. Supplementary Material Notes Author contributions. Z. Q. T., N. V. T., P. V. L., and K. M. conceptualized the idea. K. M. and N. V. T. secured the funding. L. A. T., T. H. M. L., N. T. C., N. T. T. U., and N. T. T. T. performed recruitment. L. T. K. L., C. T. N. M., T. T. H. N., and C. Q. performed sample testing. Z. Q. T. and N. V. T. wrote the original draft. All authors reviewed the article. Acknowledgment. We thank all the participants and medical staff in Do Son, Hai Phong for participating in this study. This work was supported by Victorian Government’s Medical Research Operational Infrastructure Support Program. Disclaimer. The funders had no role in the writing or submission of the article for publication. Data availability. The data underlying this article will be shared on reasonable request to the corresponding author. Financial support. This work was funding by the United Kingdom (UK) Medical Research Council and the Vietnamese Ministry of Science and Technology as part of the UK-Vietnam Research Collaboration supported by the Newton Fund (project number HNQT/SPDP/03.16). We thank Merck Sharpe & Dohme for providing the Gardasil vaccine for this study through the investigator-initiated scheme (grant number IIS-60921). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Contributor Information Nguyen Van Trang, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Le Anh Tuan, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Chu Thi Ngoc Mai, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Le Thi Khanh Ly, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Tran Hoang My Lien, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Nguyen Thanh Chung, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Dao Thi Thanh Huyen, Department of Immunology and Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. Nguyen Thi To Uyen, Do Son Health Center, Hai Phong, Vietnam. Nham Thi Tuyen Thanh, The Center for Supporting Community Development Initiatives, Hanoi, Vietnam. Tran Thi Hong Nhung, The Center for Supporting Community Development Initiatives, Hanoi, Vietnam. Chau Quang, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia. Claire Von Mollendorf, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia. Gerald Murray, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Regional WHO HPV Reference Laboratory, The Royal Women's Hospital, Parkville, Victoria, Australia; Department of Obstetrics, Gynaecology and Newborn Health, The University of Melbourne, Parkville, Victoria, Australia. Suzanne M Garland, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Regional WHO HPV Reference Laboratory, The Royal Women's Hospital, Parkville, Victoria, Australia; Department of Obstetrics, Gynaecology and Newborn Health, The University of Melbourne, Parkville, Victoria, Australia. Kathryn Bright, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Paul V Licciardi, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia. Kim Mulholland, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Department of Infectious Disease Epidemiology and International Health, London School of Tropical Medicine, London, United Kingdom. Zheng Quan Toh, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia. Supplementary Data Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author. References Associated Data Supplementary Materials